Zobrazeno 1 - 10
of 26
pro vyhledávání: ''
Autor:
Michel M van den Heuvel, David M. Burger, Rob ter Heine, Sabine Visser, Stijn L.W. Koolen, Joachim G.J.V. Aerts, Hieronymus J. Derijks, Nikki de Rouw
Publikováno v:
Cancer Chemotherapy and Pharmacology, 85, 231-235
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 85, 1, pp. 231-235
Cancer Chemotherapy and Pharmacology, 85, 231-235. Springer-Verlag
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 85, 1, pp. 231-235
Cancer Chemotherapy and Pharmacology, 85, 231-235. Springer-Verlag
Purpose Pemetrexed is a widely used cytostatic agent with an established exposure–response relationship. Although dosing is based on body surface area (BSA), large interindividual variability in pemetrexed plasma concentrations is observed. Therape
Autor:
Kim Wai Yu, Laura Kruper, Yuan Yuan, Joanne E. Mortimer, Daphne Stewart, Louise Wong, Jae Jung, Samuel Chung, Sanjeet Dadwal, Jill Cooper
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose We update a patient series that reported a high incidence of infection with Gram-positive cocci in women treated with the combination of pertuzumab and trastuzumab and further characterize this clinical problem. Patients Treating physicians a
Autor:
Campone, F, Bachelot, F, Penault-Llorca, F., Pallis, F, Agrapart, F, Pierrat, F, Poirot, F., Dubois, F., Xuereb, F, Bossard, F., Guigal-Stephan, F, Lockhart, F, Andre, F., Campone, M., Bachelot, Thomas, Pallis, A., Agrapart, Vincent, Pierrat, M., Poirot, C., Xuereb, L., Bossard, C., Guigal-Stephan, N., Lockhart, B.
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2019, 83 (4), pp.743-753. ⟨10.1007/s00280-018-03765-3⟩
Cancer Chemotherapy and Pharmacology, 2019, 83 (4), pp.743-753. ⟨10.1007/s00280-018-03765-3⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2019, 83 (4), pp.743-753. ⟨10.1007/s00280-018-03765-3⟩
Cancer Chemotherapy and Pharmacology, 2019, 83 (4), pp.743-753. ⟨10.1007/s00280-018-03765-3⟩
The primary objective of this multicentric dose allocation and dose expansion study was to determine the MTD and the DLTs of the lucitanib (a tyrosine kinase inhibitor of the FGFR/VEGFR/PDFGR pathways)/fulvestrant combination. Postmenopausal women wi
Autor:
Paul Hamberg, Guillemette E. Benoist, Inge M. van Oort, Floor J E Lubberman, Winald R. Gerritsen, David M. Burger, Nielka P. van Erp, Niven Mehra
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 84, 1179-1185
Cancer Chemotherapy and Pharmacology, 84, 6, pp. 1179-1185
Cancer Chemotherapy and Pharmacology, 84, 1179-1185
Cancer Chemotherapy and Pharmacology, 84, 6, pp. 1179-1185
Purpose Abiraterone acetate is used at a fixed oral dose of 1000 mg once daily (OD) taken fasted. By administering abiraterone acetate with food, a reduced dose can potentially be given while maintaining equivalent abiraterone exposure. Moreover, adm
Autor:
Marie Perier-Muzet, Luc Thomas, Frédérique Dijoud, Maurice Laville, Gérard Duru, Cécile Teuma, Mona Amini-Adl, Mathilde Nouvier, Denis Fouque, Stéphane Dalle, Solenne Pelletier
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2016, 78 (2), pp.419-26. ⟨10.1007/s00280-016-3086-7⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2016, 78 (2), pp.419-26. ⟨10.1007/s00280-016-3086-7⟩
International audience; PURPOSE: Vemurafenib (VMF) is a B-RAF inhibitor used in the treatment of B-RAF-V600-mutant metastatic melanomas. Reports of acute kidney injury (AKI) in patients treated with VMF are scarce. METHODS: To investigate the inciden
Autor:
Andrew T. Gabrielson, Karen Dorsch-Vogel, Hongkun Wang, Michael J. Pishvaian, Anteneh Tesfaye, Brandon G. Smaglo, Reena Jha, John L. Marshall, Aiwu Ruth He
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To determine the antitumor efficacy and tolerability of combination temozolomide (TMZ) and veliparib (ABT-888) in patients with advanced, sorafenib-refractory hepatocellular carcinoma (HCC). Methods This single-arm phase II trial enrolled pat
Autor:
Claire Larible, Catherine Cattenoz, Julien Edeline, Marianne Latournerie, Laurence Crouzet, Eveline Boucher, Samuel Le Sourd, Anne Guillygomarc'h, Florence Le Roy, Angélique Brunot, Daniel Gedouin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2015, 75 (1), pp.215--219. ⟨10.1007/s00280-014-2645-z⟩
Cancer Chemotherapy and Pharmacology, 2015, 75 (1), pp.215--219. ⟨10.1007/s00280-014-2645-z⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2015, 75 (1), pp.215--219. ⟨10.1007/s00280-014-2645-z⟩
Cancer Chemotherapy and Pharmacology, 2015, 75 (1), pp.215--219. ⟨10.1007/s00280-014-2645-z⟩
International audience; PURPOSE: Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC). The peak incidence of HCC is around 70 years. We aimed to evaluate safety and efficacy of sorafenib in the elderly population. METHODS: We
Autor:
David I. Quinn, Pierre François Clot, Jian Yin, James L. Wade, A. Craig Lockhart, James W. Mier, Wenping Zhang, John Sarantopoulos, Alain C. Mita, John C. Morris, Aiwu He, Olivier Rixe, Jimmy J. Hwang, Chung-Tsen Hsueh, Claudine Wack
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Cabazitaxel has not been studied in patients with hepatic impairment (HI). This phase I study assessed cabazitaxel safety and pharmacokinetics in patients with HI. Methods Patients with advanced, non-hematologic cancer, and normal hepatic fun
Publikováno v:
Cancer Chemotherapy and Pharmacology
With the aim to determine effective therapeutic window of electrochemotherapy, we analyzed bleomycin pharmacokinetic parameters in elderly patients. In prospective clinical study in the treatment of tumors with electrochemotherapy, blood samples of p
Autor:
Robert R. Bies, Ramesh K. Ramanathan, Abdulateef O. Aregbe, Merrill J. Egorin, David B. Solit, Chandra P. Belani, Suresh S. Ramalingam, Eric A. Sherer, Percy Ivy, Howard I. Scher
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To identify sources of exposure variability for the tumor growth inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) using a population pharmacokinetic analysis. Methods A total 67 solid tumor patients at 2 centers were gi